Q3056355 (Q3056355): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the beneficiary bot - attach the beneficiary based on the string) |
(Created claim: summary (P836): The aim of the project is to study the composition of wild and cultivated forest and marsh berry extracts (genus Vaccinium) using environmentally friendly biologically active substances, non-solvent and extraction methods of CO2 supercritical status, and to carry out an in vitro study of the pharmacological activity of extractive substances in order to obtain biopharmaceuticals and biomedicine and to develop innovative health promotion products....) |
||||||||||||||
| Property / summary | |||||||||||||||
The aim of the project is to study the composition of wild and cultivated forest and marsh berry extracts (genus Vaccinium) using environmentally friendly biologically active substances, non-solvent and extraction methods of CO2 supercritical status, and to carry out an in vitro study of the pharmacological activity of extractive substances in order to obtain biopharmaceuticals and biomedicine and to develop innovative health promotion products. The project will contribute to the implementation of the Latvian Smart Specialisation Strategy, contributing to the development of biopharmaceuticals. Research of the composition of plant products and the offer of new application solutions will promote strengthening of Latvia’s niche in the EU bioeconomy production market; The complete processing of the raw materials used will ensure the production of high added value products with a high export capacity. The scientific value of the results is determined by an in-depth study of secondary metabolites of wild and cultured Vaccinium berry using methods such as GC-MS, UPLC-MS, UPLC-ESI-TOF, preparative fractionation of extractive substances obtained, and biological activity testing to identify fractions of higher activity, but also specific substances if necessary. The novelty of the study will be based on modern scientific knowledge about an important group of plant kingdoms. The project will make an important contribution to the development of eco-innovative technologies in accordance with the generally accepted understanding of eco-innovation, as it will motivate the development of eco-friendly products (organic, eco-) production while strengthening Latvia’s position as eco-producers in the EU and other markets. The project will focus on the development of environmentally friendly technologies, ensuring the extraction of innovative biopharmaceutical products. The following results are expected during the project life cycle: 5 original scientific articles that will be submitted for publication in journals or conference articles included in Web of Science or SCOPUS databases, including 1 original scientific article, which will be submitted for publication in the written collection, whose citation index reaches at least 50 percent of the industry average citation index, a patent-protected product and its method of obtaining, an innovative, health-enhancing product prototype, as well as product usage recommendations.The project is planned to start on February 1, 2017 and be implemented by 31 January 2020 (36 months). The project will be implemented by the University of Latvia in cooperation with a partner – SIA “Silv EXPO” as a non-economic Industrial Research. The total eligible costs of the project are EUR 644456.79, incl. ERDF co-financing of 85 %, – EUR 547788.27. Compliance of the project with the OECD Sectoral Classification of Sciences – 1.5. Land and environmental sciences, 2.9. Environmental biotechnology and 3.1. Basic medical sciences (pharmacology and pharmacy). Keywords: Pharmacological activity of polyphenols, genus Vaccinum, secondary metabolites. (English) | |||||||||||||||
| Property / summary: The aim of the project is to study the composition of wild and cultivated forest and marsh berry extracts (genus Vaccinium) using environmentally friendly biologically active substances, non-solvent and extraction methods of CO2 supercritical status, and to carry out an in vitro study of the pharmacological activity of extractive substances in order to obtain biopharmaceuticals and biomedicine and to develop innovative health promotion products. The project will contribute to the implementation of the Latvian Smart Specialisation Strategy, contributing to the development of biopharmaceuticals. Research of the composition of plant products and the offer of new application solutions will promote strengthening of Latvia’s niche in the EU bioeconomy production market; The complete processing of the raw materials used will ensure the production of high added value products with a high export capacity. The scientific value of the results is determined by an in-depth study of secondary metabolites of wild and cultured Vaccinium berry using methods such as GC-MS, UPLC-MS, UPLC-ESI-TOF, preparative fractionation of extractive substances obtained, and biological activity testing to identify fractions of higher activity, but also specific substances if necessary. The novelty of the study will be based on modern scientific knowledge about an important group of plant kingdoms. The project will make an important contribution to the development of eco-innovative technologies in accordance with the generally accepted understanding of eco-innovation, as it will motivate the development of eco-friendly products (organic, eco-) production while strengthening Latvia’s position as eco-producers in the EU and other markets. The project will focus on the development of environmentally friendly technologies, ensuring the extraction of innovative biopharmaceutical products. The following results are expected during the project life cycle: 5 original scientific articles that will be submitted for publication in journals or conference articles included in Web of Science or SCOPUS databases, including 1 original scientific article, which will be submitted for publication in the written collection, whose citation index reaches at least 50 percent of the industry average citation index, a patent-protected product and its method of obtaining, an innovative, health-enhancing product prototype, as well as product usage recommendations.The project is planned to start on February 1, 2017 and be implemented by 31 January 2020 (36 months). The project will be implemented by the University of Latvia in cooperation with a partner – SIA “Silv EXPO” as a non-economic Industrial Research. The total eligible costs of the project are EUR 644456.79, incl. ERDF co-financing of 85 %, – EUR 547788.27. Compliance of the project with the OECD Sectoral Classification of Sciences – 1.5. Land and environmental sciences, 2.9. Environmental biotechnology and 3.1. Basic medical sciences (pharmacology and pharmacy). Keywords: Pharmacological activity of polyphenols, genus Vaccinum, secondary metabolites. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: The aim of the project is to study the composition of wild and cultivated forest and marsh berry extracts (genus Vaccinium) using environmentally friendly biologically active substances, non-solvent and extraction methods of CO2 supercritical status, and to carry out an in vitro study of the pharmacological activity of extractive substances in order to obtain biopharmaceuticals and biomedicine and to develop innovative health promotion products. The project will contribute to the implementation of the Latvian Smart Specialisation Strategy, contributing to the development of biopharmaceuticals. Research of the composition of plant products and the offer of new application solutions will promote strengthening of Latvia’s niche in the EU bioeconomy production market; The complete processing of the raw materials used will ensure the production of high added value products with a high export capacity. The scientific value of the results is determined by an in-depth study of secondary metabolites of wild and cultured Vaccinium berry using methods such as GC-MS, UPLC-MS, UPLC-ESI-TOF, preparative fractionation of extractive substances obtained, and biological activity testing to identify fractions of higher activity, but also specific substances if necessary. The novelty of the study will be based on modern scientific knowledge about an important group of plant kingdoms. The project will make an important contribution to the development of eco-innovative technologies in accordance with the generally accepted understanding of eco-innovation, as it will motivate the development of eco-friendly products (organic, eco-) production while strengthening Latvia’s position as eco-producers in the EU and other markets. The project will focus on the development of environmentally friendly technologies, ensuring the extraction of innovative biopharmaceutical products. The following results are expected during the project life cycle: 5 original scientific articles that will be submitted for publication in journals or conference articles included in Web of Science or SCOPUS databases, including 1 original scientific article, which will be submitted for publication in the written collection, whose citation index reaches at least 50 percent of the industry average citation index, a patent-protected product and its method of obtaining, an innovative, health-enhancing product prototype, as well as product usage recommendations.The project is planned to start on February 1, 2017 and be implemented by 31 January 2020 (36 months). The project will be implemented by the University of Latvia in cooperation with a partner – SIA “Silv EXPO” as a non-economic Industrial Research. The total eligible costs of the project are EUR 644456.79, incl. ERDF co-financing of 85 %, – EUR 547788.27. Compliance of the project with the OECD Sectoral Classification of Sciences – 1.5. Land and environmental sciences, 2.9. Environmental biotechnology and 3.1. Basic medical sciences (pharmacology and pharmacy). Keywords: Pharmacological activity of polyphenols, genus Vaccinum, secondary metabolites. (English) / qualifier | |||||||||||||||
point in time: 15 July 2021
| |||||||||||||||
Revision as of 12:34, 15 July 2021
Project Q3056355 in Latvia
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3056355 in Latvia |
Statements
547,788.27 Euro
0 references
644,456.79 Euro
0 references
1 February 2017
0 references
31 January 2020
0 references
LATVIJAS UNIVERSITĀTE
0 references
56°56'12.12"N, 24°5'50.71"E
0 references
56°57'32.40"N, 24°6'35.50"E
0 references
Projekta mērķis ir izpētīt savvaļas un kultivētu mežu un purvu ogu (Vaccinium ģints) ekstraktvielu sastāvu, izmantojot videi draudzīgas bioloģiski aktīvo vielu bezsolventu un CO2 superkritiskā stāvokļa ekstrakcijas metodes, un veikt padziļinātu ekstraktvielu farmakoloģiskās aktivitātes izpēti ar in vitro metodēm, lai iegūtu biofarmācijā un biomedicīnā izmantojamas vielas un izstrādātu inovatīvus veselības veicināšanas produktus. Projekts sekmēs Latvijas Viedās specializācijas stratēģijas īstenošanu, sniedzot ieguldījumu biofarmācijas attīstībā. Augu produktu sastāva izpēte un jaunu izmantošanas risinājumu piedāvājums sekmēs Latvijas nišas nostiprināšanu ES bioekonomikas produkcijas tirgū; izmantoto izejvielu kompleksa pārstrāde nodrošinās augstas pievienotās vērtības produktu ražošanu ar lielu eksportspēju. Rezultātu zinātnisko vērtību nosaka padziļināta savvaļas un kultivētu Vaccinium ģints ogu sekundāro metabolītu profila izpēte, izmantojot tādas metodes kā GC-MS, UPLC-MS, UPLC-ESI-TOF, iegūto ekstraktvielu preparatīvā frakcionēšana un bioloģiskās aktivitātes testēšana, lai identificētu augstāko aktivitāti nodrošinošas frakcijas, bet, ja nepieciešams, izdalītu un identificētu arī konkrētas vielas. Pētījuma novitāte būs atbilstoši mūsdienu zinātnes līmenim iegūta informācija par nozīmīgu augu valsts grupu. Projekts sniegs nozīmīgu ieguldījumu eko-inovatīvu tehnoloģiju attīstībai atbilstoši vispārpieņemtai eko-inovācijas izpratnei, jo motivēs videi draudzīgas produkcijas (bioloģiskās, eko-) ražošanas attīstību vienlaikus nostiprinot Latvijas, kā ekoprodukcijas valsts, pozīciju ES un citos tirgos. Projekta ietvaros paredzēts orientēties uz videi draudzīgu tehnoloģiju attīstību, nodrošinot inovatīvu biofarmācijas produktu ieguvi. Projekta dzīves cikla laikā paredzēti šādi rezultāti: 5 oriģināli zinātniskie raksti, kas tiks iesniegti publicēšanai Web of Science vai SCOPUS datubāzēs iekļautos žurnālos vai konferenču rakstu krājumos, t.sk. 1 oriģināls zinātniskais raksts, kas tiks iesniegts publicēšanai rakstu krājumā, kura citēšanas indekss sasniedz vismaz 50 procentus no nozares vidējā citēšanas indeksa, ar patentu aizsargāts produkts un tā iegūšanas metode, inovatīva, veselību veicinoša produkta prototips, kā arī produkta izmantošanas ieteikumi.Projekta darbību paredzēts uzsākt 2017.gada 1.februāri un īstenot līdz 2020.gada 31.janvārim (36 mēneši). Projektu īstenos Latvijas Universitātes sadarbībā ar partneri – SIA “Silv EXPO” kā ne-saimniecisku Rūpniecisku pētījumu. Projekta kopējās attiecināmās izmaksas sastāda 644 456.79 EUR, t.sk. ERAF līdzfinansējums 85%, apmērā – 547 788.27 EUR. Projekta atbilstība OECD zinātņu nozaru klasifikācijai - 1.5. Zemes un vides zinātnes, 2.9. Vides biotehnoloģija un 3.1. Bāzes medicīnas zinātnes (farmakoloģija un farmācija). Atslēgas vārdi: polifenoli, Vaccinum ģints, sekundārie metabolīti, farmakoloģiskā aktivitāte. (Latvian)
0 references
The aim of the project is to study the composition of wild and cultivated forest and marsh berry extracts (genus Vaccinium) using environmentally friendly biologically active substances, non-solvent and extraction methods of CO2 supercritical status, and to carry out an in vitro study of the pharmacological activity of extractive substances in order to obtain biopharmaceuticals and biomedicine and to develop innovative health promotion products. The project will contribute to the implementation of the Latvian Smart Specialisation Strategy, contributing to the development of biopharmaceuticals. Research of the composition of plant products and the offer of new application solutions will promote strengthening of Latvia’s niche in the EU bioeconomy production market; The complete processing of the raw materials used will ensure the production of high added value products with a high export capacity. The scientific value of the results is determined by an in-depth study of secondary metabolites of wild and cultured Vaccinium berry using methods such as GC-MS, UPLC-MS, UPLC-ESI-TOF, preparative fractionation of extractive substances obtained, and biological activity testing to identify fractions of higher activity, but also specific substances if necessary. The novelty of the study will be based on modern scientific knowledge about an important group of plant kingdoms. The project will make an important contribution to the development of eco-innovative technologies in accordance with the generally accepted understanding of eco-innovation, as it will motivate the development of eco-friendly products (organic, eco-) production while strengthening Latvia’s position as eco-producers in the EU and other markets. The project will focus on the development of environmentally friendly technologies, ensuring the extraction of innovative biopharmaceutical products. The following results are expected during the project life cycle: 5 original scientific articles that will be submitted for publication in journals or conference articles included in Web of Science or SCOPUS databases, including 1 original scientific article, which will be submitted for publication in the written collection, whose citation index reaches at least 50 percent of the industry average citation index, a patent-protected product and its method of obtaining, an innovative, health-enhancing product prototype, as well as product usage recommendations.The project is planned to start on February 1, 2017 and be implemented by 31 January 2020 (36 months). The project will be implemented by the University of Latvia in cooperation with a partner – SIA “Silv EXPO” as a non-economic Industrial Research. The total eligible costs of the project are EUR 644456.79, incl. ERDF co-financing of 85 %, – EUR 547788.27. Compliance of the project with the OECD Sectoral Classification of Sciences – 1.5. Land and environmental sciences, 2.9. Environmental biotechnology and 3.1. Basic medical sciences (pharmacology and pharmacy). Keywords: Pharmacological activity of polyphenols, genus Vaccinum, secondary metabolites. (English)
15 July 2021
0 references
Jelgavas iela 1, Rīga, LV-1004
0 references
Alberta iela 12 - 2, Rīga, LV-1010
0 references
Identifiers
1.1.1.1/16/A/047
0 references